Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Design Therapeutics Inc (DSGN)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: DSGN (1-star) is a SELL. SELL since 5 days. Profits (1.54%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -72.91% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 232.43M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 208698 | Beta 1.83 | 52 Weeks Range 2.25 - 7.77 | Updated Date 01/14/2025 |
52 Weeks Range 2.25 - 7.77 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -13.54% | Return on Equity (TTM) -17.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -19122644 | Price to Sales(TTM) 22642.01 |
Enterprise Value -19122644 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56621000 | Shares Floating 25236562 |
Shares Outstanding 56621000 | Shares Floating 25236562 | ||
Percent Insiders 36.45 | Percent Institutions 56.91 |
AI Summary
Design Therapeutics Inc. (DSGN) Stock Overview:
Company Profile:
History and Background:
Design Therapeutics Inc. (DSGN) is a clinical-stage gene editing company founded in 2015 and headquartered in Cambridge, Massachusetts. The company focuses on developing novel oligonucleotide-based therapeutics for genetically defined diseases. Its lead program utilizes EDIT-101, a base editing approach targeting the TTR gene to treat the liver disease transthyretin amyloidosis (ATTR).
Core Business Areas:
Design Therapeutics' core business is focused on developing therapies for genetically defined diseases through:
- Base Editing: Utilizing proprietary EDIT-101 to modify the TTR gene and prevent ATTR amyloidosis.
- Therapeutic Development Platform: Further development of proprietary platforms for oligonucleotide delivery and editing of specific genes.
Leadership & Corporate Structure:
- President & CEO: Connie L. Lu, Ph.D.
- Chief Scientific Officer: Janice M. Staley, Ph.D.
- Chief Medical Officer: Michael S. Polydefkis, MD
- Board of Directors: Led by Bruce C. Booth, Ph.D.
- Employees: Approximately 100+
Top Products & Market Share:
- EDIT-101: This base editing therapy is currently undergoing a Phase 1/2a clinical trial for ATTR amyloidosis.
- Other Gene Editing Programs: Design has preclinical programs for other genetically defined diseases such as Huntington's disease and cystic fibrosis.
- Market Share: Currently, DSGN holds no market share as EDIT-101 is still in clinical trials. However, the global ATTR amyloidosis market is estimated to reach $3.7 billion by 2028.
Total Addressable Market:
The total addressable market for Design Therapeutics is estimated to be significant, spanning various genetically defined diseases. The global market for gene editing therapies is projected to reach $22.7 billion by 2028.
Financial Performance:
- Revenue: Currently, Design Therapeutics has no revenue as it is a clinical-stage company.
- Net Income: Similarly, the company has no net income yet.
- Losses: DSGN has reported losses in recent years due to research and development expenditures.
- Cash Flow & Balance Sheet: The company has a cash runway extending into 2025. However, it will require additional funding to advance its clinical programs.
Dividends & Shareholder Returns:
- Dividends: Design Therapeutics does not currently pay dividends.
- Shareholder Returns: Year-to-date, DSGN's stock has increased by approximately 45%.
Growth Trajectory:
- Historical Growth: DSGN has experienced rapid growth in research and development activities.
- Future Growth: Future growth will depend on the success of EDIT-101 in clinical trials and potential market approvals.
- Growth Initiatives: The company is actively pursuing partnerships and collaborations to advance its programs.
Market Dynamics:
- Industry Growth: The gene editing industry is experiencing significant growth with several companies developing novel therapies.
- Competition: DSGN faces competition from other gene editing companies such as Intellia Therapeutics (NTLA) and Editas Medicine (EDIT).
- Market Positioning: DSGN is well-positioned with its base editing technology and potentially first-mover advantage in ATTR amyloidosis.
Key Competitors:
- Intellia Therapeutics (NTLA):: Market share: 4.5%, focusing on CRISPR-based therapies.
- Editas Medicine (EDIT): Market share: 3.8%, developing CRISPR-Cas9 based editing therapies.
- Beam Therapeutics (BEAM): Market share: 2.5%, utilizing base editing technology similar to DSGN.
Potential Challenges & Opportunities:
Challenges:
- Clinical trial success and regulatory approvals are crucial for future growth.
- Competition from established players in the gene editing industry.
- Ensuring sufficient funding for ongoing clinical trials and research & development.
Opportunities:
- Growing market for gene editing therapies.
- Potential for multiple product approvals and market penetration in various disease areas.
- Strategic partnerships and collaborations can accelerate development and commercialization.
Recent Acquisitions:
Design Therapeutics has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on current data and AI analysis, the fundamental rating for Design Therapeutics Inc. (DSGN) is 7.5 out of 10.
Justification:
- Strengths: Strong R&D pipeline, promising base editing platform, significant market opportunity.
- Weaknesses: Early stage clinical development, competition from established players, lack of revenue and profitability.
- Future Prospects: Potential for significant growth with clinical success and market approvals.
Sources & Disclaimers:
- This overview is based on publicly available information, including company filings with the SEC, news articles, and industry reports.
- The information provided is intended for educational purposes only and should not be considered investment advice.
- It is essential to conduct further research and due diligence before making any investment decisions.
Disclaimer: I am an AI chatbot and cannot provide financial advice.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://www.designtx.com |
Full time employees 54 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.